Pfizer Canada Gives $440K to PGx-Based Pediatric Drug Toxicity Study | GenomeWeb
NEW YORK (GenomeWeb News) — Pfizer Canada has given CA$500,000 ($440,000) to a Canadian research project studying the pharmacogenomics of pediatric drug toxicity, the company said today.
 
The project, Genotype-Specific Approaches to Therapy in Childhood initiative, or GATC, plans to study DNA from children who have experienced adverse drug reactions in hopes of identifying biomarkers linked to severe drug toxicity.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.